Navigation Links
Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in World's Largest Stent Registry
Date:9/2/2007

atients comprised 72.4 percent of the population (5,157 patients) and included patients with acute MI, small vessels, long lesions, in-stent restenosis, and bifurcations, representing lesions not studied in the TAXUS IV and TAXUS ATLAS pivotal randomized controlled trials. Despite the higher complexity, patients in this group demonstrated an overall TAXUS Liberte stent related cardiac event rate of 4.6 percent and a stent thrombosis rate of 1.0 percent.

CAUTION: The TAXUS Liberte stent is an investigational device and is not for sale in the United States.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, product performance, competitive offerings, procedural volume, overall market size and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implemen
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reforming FDA: Focus on safety, let market judge efficacy
2. Funds will support public safety communications interoperabilty
3. High interest forces delay in food safety symposium
4. Human factors and IT: Designing for patient safety
5. UW Medical Foundation CEO shares his vision on the state of health care and patient safety
6. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
7. Thompson receives leadership award for technology solutions for patient safety
8. Thermal Cycling Profile for Standard PCR
9. PCR Polymerases Application Profiles
10. Setting up a kinase profiler with IMAP
11. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Patients who were treated with a statin ... were significantly more likely to survive than those who ... JAMA Neurology . This study was conducted by ... of cholesterol-lowering statins can improve survival in victims of ... or obstruction of a blood vessel that blocks blood ...
(Date:9/22/2014)... researchers at the USC Viterbi School of Engineering, ... microfluidic system quickly and cheaply by simply snapping ... systems are used in many fields including engineering, ... of fluids for use in applications such as ... testing, and synthetic chemistry. Traditionally, microfluidic devices are ...
(Date:9/22/2014)... Minnesota electrical engineering researchers have developed a unique ... mechanical transportation of light. The discovery could have ... optical devices for computation and communication. , The ... computer engineering assistant professor Mo Li and his ... and will appear in the October issue of ...
(Date:9/22/2014)... 22, 2014 US demand to rise 3.9% ... biocides is forecast to rise 3.9 percent per year ... is projected to increase 1.3 percent per year to ... rebound in construction expenditures will support demand for biocides ... while growth in consumer spending and manufacturing output will ...
Breaking Biology Technology:Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Engineers show light can play seesaw at the nanoscale 2US Biocides Market 2US Biocides Market 3
... and Webcast on November 9 at 8:00 a.m. ... Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical ... matrix, today reported financial,results for the three and ... unique capabilities in navigating the complexities of the,extracellular ...
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today reported financial ... Net loss for the quarter and nine months ended ... per share and $0.46 per share,compared to a net loss ... share, in the same periods last year. Revenues were ...
... 8 Inverness Medical,Innovations, Inc. (Amex: IMA ), ... market and other conditions, 7,000,000 shares of its common,stock ... public offering. Certain selling stockholders of the Company,are also ... stock in the,offering. The Company expects to grant the ...
Cached Biology Technology:Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 2Kosan Announces Third Quarter 2007 Financial Results 3Kosan Announces Third Quarter 2007 Financial Results 4Kosan Announces Third Quarter 2007 Financial Results 5Kosan Announces Third Quarter 2007 Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 7Inverness Medical Innovations Announces Proposed Public Offering of Common Stock 2Inverness Medical Innovations Announces Proposed Public Offering of Common Stock 3
(Date:9/23/2014)... Pattern formation is essential in the development of animals ... how can genetic information be translated in a reliable ... , The French-flag model of stripe formation is ... by the different colours of the French flag, is ... i.e. at high, middle or low concentrations of the ...
(Date:9/23/2014)... 23 de septiembre de 2014 ... 1290 Infinity II LC, el nuevo instrumento ... su portafolio de cromatografía líquida. El sistema ... de laboratorio que alcancen nuevos niveles de ... uso y capacidad de integración de laboratorio. ...
(Date:9/22/2014)... Researchers at the University of Chicago have shown that ... (ICU) only a handful of pathogenic microbe species remain ... pathogens and discovered that some can become deadly when ... to illness. , The findings, published in mBio ... for Microbiology, may lead to better monitoring and treatment ...
Breaking Biology News(10 mins):Recreating the stripe patterns found in animals by engineering synthetic gene networks 2Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 2Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 3Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3
... best-studied single-celled organisms around, is a master of industrial efficiency. ... just one product: itself. It exists to make copies of ... the lowest possible cost, with the greatest possible efficiency. ... by the energy and resources it uses to maintain its ...
... facial structure of an ancient relative of modern humans ... hard nuts and seeds as part of a survival ... team of researchers that includes Florida State University,s Dennis ... Proceedings of the National Academy of Science, ...
... gearing up to return to Russia to oversee preparations for ... launch on 16 March 2009. This follows implementation of the ... delayed the launch of GOCE by Eurockot Launch Services last ... at the Plesetsk Cosmodrome in northern Russia to arrange logistical ...
Cached Biology News:Bacteria are models of efficiency 2March launch planned for ESA's gravity mission 2
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
IHC Select Anti-p53, prediluted,wild & mutant, a.a. 19-26, clone DO-7 Immunogen: Human p53 Available Date: 37775...
Feline Rhinotracheitis Virus...
Biology Products: